Adam Spivak, MD
After receiving an MD degree from the University of Maryland School of Medicine in 2002, Dr. Spivak performed housestaff training in Internal Medicine as a member of the Osler Medical Residency at Johns Hopkins Hospital from 2002 to 2005. He served as Assistant Chief of Service for the Osler Medical Residency during the 2006-07 academic year, and afterward joined the Infectious Diseases fellowship program in the Johns Hopkins University School of Medicine. Dr. Spivak spent the research years of fellowship in the laboratory of his mentor, Robert Siliciano, studying long-lived cellular reservoirs of HIV and the effect of antiretroviral therapy on different cell types susceptible to HIV infection.
During the 2010-11 academic year, Dr. Spivak was involved in several research projects. He worked with Joel Blankson, an Associate Professor in the Division of Infectious Diseases at Johns Hopkins, to determine the frequency of HIV infection in circulating monocytes compared to T cells among different groups of HIV infected patients, including patients who maintain long-term control over the infection without antiretroviral therapy (known as elite suppressors). This work was recently accepted for publication by the Journal of Virology. He spent the majority of his time helping to run a pilot clinical trial aimed at HIV eradication with collaborators from University of California, San Francisco. This trial involves recruitment of 20 HIV infected participants on stable antiretroviral therapy, who are given two weeks of an FDA-approved drug that has demonstrated the ability in laboratory models to reactivate HIV in latently infected T cells. This trial has accrued 13 participants to date and will likely conclude in the fall of 2011.
In May 2011, Dr. Spivak was awarded a challenge grant from the Bill and Melinda Gates Foundation to pursue a high throughput in vitro screen to identify novel compounds that are able to specifically induce apoptosis in HIV infected cells. He was promoted to Instructor in the Department of Medicine in order to serve as the principal investigator of this project. Adam has accepted a job in the Division of Infectious Diseases at the University of Utah School of Medicine beginning in October 2011, where he will continue to perform laboratory-based research focused on eradication of HIV reservoirs.
To learn more about Johns Hopkins Department of Neurology: Neuroinfectious Disease Fellowship, please call: 443-287-0571.